US Patent

US8618109 — Piperazine-substituted benzothiophenes for treatment of mental disorders

Method of Use · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2026-04-12 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a class of heterocyclic compounds, specifically piperazine-substituted benzothiophenes, for treating mental disorders.

USPTO Abstract

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-543 — Rexulti
U-543 — Rexulti
U-543 — Rexulti
U-543 — Rexulti
U-543 — Rexulti
U-543 — Rexulti

Patent Metadata

Patent number
US8618109
Jurisdiction
US
Classification
Method of Use
Expires
2026-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.